All T-cell therapy articles
-
NewsJ&J wagers on next cell therapy frontier with $2.6bn Sail Bio acquisition option
In vivo-focused collaboration has scope to considerably boost therapeutic innovation and address unmet need in immune-mediated diseases.
-
NewsCARsgen wins first global approval of CAR T therapy for solid tumours
Approval of the autologous cell therapy satri-cel in China fills the gap in later-line treatment for advanced gastric cancer.
-
NewsNovel CAR T manufacturing process significantly cuts production time
Efficacy findings comparable to those of existing CAR T cell therapies for relapsed/refractory multiple myeloma (r/r MM).
-
ReportPharma Horizons: Cell and Gene Therapy
EPR’s 2026 cell and gene therapy report covers the key developments in manufacturing, regulation, drug delivery, process development and beyond.
-
NewsMajor immunotherapy trial sees survival benefit in solid tumours
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
-
NewsAstraZeneca to boost cell therapy operations with $300m manufacturing investment
Investment in the US manufacturing facility will accelerate AstraZeneca’s ambition to make next-generation cell therapy a reality, the company asserts.
-
NewsCAR T therapy exhibits encouraging proficiency in R/R LBCL
The first study assessing Yescarta® as second-line therapy for transplant ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL) demonstrated durable remission rate in a Phase II trial.
-
NewsUK ATMP clinical trials report 2022 published
T cells were revealed as the most commonly investigated cell type continuing to increase, found CGT Catapult's 2022 UK ATMP clinical trials report.
-
NewsT-cell therapy helps overcome stem cell transplant viral infections
A T-cell therapy that targets six viruses commonly contracted by haematology patients after allogeneic stem cell transplantation, offered 95 percent response in a study.